Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Essential thrombocythemia with MPL W515S mutation

Christopher Thorburn, Marc D. Smith

Blood (2024) 144 (3): 340.

https://doi.org/10.1182/blood.2024024714

Published: 2024

Journal Articles

Screening Cerebrospinal Fluid for Aggressive B-Cell Lymphoma: Significance of Clonal Populations Found with 8-Color Flow Cytometry

Carrie I Ho, Paolo Lopedote, Olivia Lin, Jonathan R Fromm, Ajay K Gopal, Filippo Milano, Stephen D Smith

Blood (2023) 142 (Supplement 1): 6263.

https://doi.org/10.1182/blood-2023-181450

Published: 2023

Journal Articles

Evaluation of the Thermo Fisher Oncomine Myeloid MRD DNA Assay on the Ion Torrent Platform

Candace D Smith, Desiree Unselt, Nagendran Muthusamy, Lauren Frady, Fernando Torres, Jennifer Sims

Blood (2023) 142 (Supplement 1): 7174.

https://doi.org/10.1182/blood-2023-189525

Published: 2023

Journal Articles

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Carrie I Ho, Ajay K Gopal, Chaitra S Ujjani, Ryan C Lynch, Christina Poh, Jenna M Voutsinas, Qian Wu, Jacquelin Vandermeer, Jonathan R Fromm, Stephen D Smith

Blood (2023) 142 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2023-177682

Published: 2023

Journal Articles

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 2224.

https://doi.org/10.1182/blood-2023-184728

Published: 2023

Journal Articles

Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification

Carrie I Ho, David Wu, Qian Wu, Kevin Ng, Jenna M Voutsinas, Ryan C Lynch, Manoj P Menon, Christina Poh, Mazyar Shadman, Brian G Till, Chaitra S Ujjani, Ajay K Gopal, Stephen D Smith

Blood (2023) 142 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2023-181440

Published: 2023

Journal Articles

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 613.

https://doi.org/10.1182/blood-2023-174209

Published: 2023

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Christina Poh, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Michi M Shinohara, Phuong T Vo, Mazyar Shadman, Chaitra S Ujjani, Ryan C Lynch, Brian G Till, Stephen D Smith, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 1708.

https://doi.org/10.1182/blood-2023-184314

Published: 2023

Journal Articles

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Ryan C Lynch, Christina Poh, Mazyar Shadman, Brian G Till, Stephen D Smith, Chaitra S Ujjani, Susan Ottemiller, Melissa Mary Fessel, Bonnie Joy, Jacob DeBell, Joshua Dizon, Ryan Park, Heather Rasmussen, Jacquelin Vandermeer, Jenna M Voutsinas, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2023-174292

Published: 2023

Journal Articles

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Laura Samples, Chaitra S Ujjani, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Stephanie Louie, Christina Poh, Stephen D Smith, Brian G Till, David G Maloney, Ajay K Gopal, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2023-187129

Published: 2023

Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Blood (2023) 142 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2023-181130

Published: 2023

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Ilaria Romano, Jordan Gauthier, Ryan C Lynch, Ajay K Gopal, Alexandre V Hirayama, Kikkeri N Naresh, Alireza Torabi, Stephen D Smith, Brian G Till, David G Maloney, Chaitra S Ujjani, Christina Poh, Filippo Milano, Aude G Chapuis, Mazyar Shadman, Lorenzo Iovino

Blood (2023) 142 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2023-181956

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Laura Samples, Sirin Khajaviyan, Ryan C Lynch, Mehrdad Shakib-Azar, Christine Crider, Margie Fredericks, Hania Shakalia, Stephanie Louie, David G Maloney, Christina Poh, Brian G Till, Stephen D Smith, Ajay K Gopal, Chaitra S Ujjani, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2023-186775

Published: 2023

Journal Articles

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Blood (2023) 142 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2023-179547

Published: 2023

Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Blood (2023) 141 (21): 2576–2586.

https://doi.org/10.1182/blood.2022019254

Published: 2023

Includes: Supplemental data

Journal Articles

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2022) 140 (Supplement 1): 6477–6479.

https://doi.org/10.1182/blood-2022-157595

Published: 2022

Journal Articles

Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Steven I. Park, Stephen M. Ansell, Sharmila Giri, Jakub Svoboda, Stephen D Smith, Tatyana Feldman, Elizabeth L. Budde, Andrew J Ness, Yunsik Choi, Philip J Bierman, Hun Ju Lee

Blood (2022) 140 (Supplement 1): 1751–1752.

https://doi.org/10.1182/blood-2022-159258

Published: 2022

NARROW

Essential thrombocythemia with MPL W515S mutation

Screening Cerebrospinal Fluid for Aggressive B-Cell Lymphoma: Significance of Clonal Populations Found with 8-Color Flow Cytometry

Evaluation of the Thermo Fisher Oncomine Myeloid MRD DNA Assay on the Ion Torrent Platform

Pembrolizumab with Rituximab in Relapsed/Refractory Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for Large B-Cell Lymphoma

Heterogeneity of TP53 Mutations in Mantle Cell Lymphoma- Challenges in Risk Stratification and Subclassification

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Intent to Treat Allogeneic Stem Cell Transplantation Outcomes in Relapsed/Refractory T-Cell Lymphomas

Early Complete Responses with Mosunetuzumab Monotherapy in Treatment-Naïve Follicular and Marginal Zone Lymphomas with Only Low-Grade Cytokine Release Syndrome

Clinical Outcomes in Patients Treated with Both Covalent Btkis and Venetoclax and the Significance of “Double-Refractory” Status in Patients with CLL/SLL

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Predictors of Outcomes with Venetoclax-Based Treatment in Patients with Progressive Disease or Intolerance after Covalent BTK Inhibitors

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only